transplant Flashcards
most important HLA for recipient/donor matching?
HLA-DR***, A and B (on all nucleated cells)
type IV hypersensitivity
what does cross match entail? reagents.
recipient serum with donor lymphocytes.
to r/o hyperacute rejection.= type II hypersensitivity
1 and 2 malignancy after transplant
squamous skin ca»_space;> PTLD (EBV)
how to tx post-txp EBV
reduce immunosuppression; and rule out PTLD
how to tx PTLD
decrease immunosuppression
rituximab (anti CD20) decrease
+/- chemotherapy or XRT to decrease size of tumor
mycophenalate mofetil MOA?
inhibit de novo purine synthesis to stop T CELL GROWTH.
adverse: GI mostly, nausea, dyspepsia, diarrhea, bloating, leukopenia, anemia, thrombocytopenia (PANCYTOPENIA!)
cyclosporin MOA?
binds cyclophilin to inhibit calcineurin to decrease cytokine (IL-2) synth.
metabolism: LIVER.
tacrolimus MOA?
like cyclosporin (calcineurin inhibitor/IL-2) but more potent. via FKBP/p450.
metabolism: less LIVER.
adverse: tremor, HA, seizure, nephrotox, HTN, alopecia, hyperK, hypoMg, GI sx, DM
what txp med has more DM, GI, mood changes?
tacrolimus
cyclosporine vs tacrolimus excretion
LIVER… but more in cyclosporine
sirolimus MOA?
binds FKBP like tac but inhibits mammalian target of rapamycin (mTOR) to decrease T and B cell response to IL-2.
LESS* NEPHROTOX* compared to tac or cyclosporin.
side effects: hyperTg, impaired wound healing, thrombocytopenia, leukopenia, anemia
sirolimus side effect?
interstitial lung dz and wound healing issues
has no nephrotoxicity (unlike tacrolimus and cyclosporine)
antithymocyte globulin MOA?
POLYCLONAL Abs against T cell antigens CD2,3,4…. then cytolytic (via COMPLEMENT)
SE: cytokine release syndrome, PTLD, myelosuppression
types of rejection?
hyperacute, accelerated, acute cellular, acute humeral, chronic.
hyperacute rejection?
min-hrs = preformed Abs Type II (I.e. ABO)
tx: re-transplant
accelerated rejection?
<1 wk = sensitized T cells to donor HLA
tx: increase Rx, steroids
acute cellular rejection?
after 1 wk.
T cells to HLA Ag
tx: immunosuppresion
acute humeral rejection?
after 1 wk.
Abs to donor Ags
tx: steroids, Ab therapy, plasmapharesis.
chronic rejection?
mos-years.
Abs formed and T cells sensitized… partially type IV +Ab formation
MC: HLA incompatibility
tx: immunosuppresion, retxp
new proteinuria after kidney txp?
renal vein thrombosis.
pathology of acute rejection in kidney txp?
1-6 mos…
Bx: tubulitis (vasculitis with more severe form), lymphocytic infiltration of the graft… membrane damage… apoptosis of graft cells
sx: fever, chills, malaise, arthralgia, AKI obv
5 yr kidney graft survival?
70%.
65 cad, 75 liv
MC cause of death after kidney transplant?
MI
how long extended survival after kidney transplant?
15 years.
UC and liver txp?
cannot txp if active ulcerative colitis.
MC cause of liver txp?
HCV.
what MELD has survival benefit after txp?
> 15.
HBV treatment after liver txp?
HBIG and lamivudine to prevent re infection.
MC arterial anomaly in liver txp?
RHA off SMA
early vs late hepatic aa thrombosis sx?
early: fulminant hepatic failure.
late: biliary strictures (blood supply from aa) and MC: ABSCESSES
acute rejection in liver txp?
T cells against blood vessels
path: portal triad lymphocytosis, endothelitis, bile duct injuries
chronic rejection in liver txp?
disappearing bile ducts (Ab and T cells attack ducts) and get obstruction with portal fibrosis
5 yr survival rate liver txp
70%.
how long does it take for liver to regenerate?
6-8 weeks.
what is donor hepatectomy in adult vs child?
adult: RIGHT lobectomy
child: left lateral (2 + 3)
pancreatic txp arterial and venous supply from donor?
celiac aa and SMA; portal
pancreatic enteric supply from donor?
D2 with ampulla and pancreas (anastomose: donor duo to recipient bowel)
where does pancreas go to txp?
on iliacs.
benefits of simult PK txp?
fix retinopathy
fix neuropathy
fix nerve conduction slowing
fix autonomic dysfunction (gastroparesis)
fix orthostatic hypotension
what will not REVERSE with simult PK txp for DM?
microvascular disease.
MC complication after PK txp?
venous thrombosis (hard to tx).
rejection signs in PK txp
increase glucose, amylase
fever
WBC
storage of donor organs?
heart: 6 hr
lung: 6 hr
liver: 24 hr
kidney: 48 hr
what bx to you get routinely after heart txp?
RV to assess for rejection.
acute rejection path in heart txp?
perivascular lymphocytic infiltrate with grades of myocyte inflammation and necrosis
cause of early vs late death after heart txp?
early: infection
late: chronic rejection = chronic allograft vasculopathy (coronary atherosclerosis)
survival increase after heart transplant
transplant <1 yr prognosis… get 10 years (median)
survival increase after lung transplant
transplant < 1 yr prognosis… get 5 years (median)
cause of early vs late death after lung txp?
early: reperfusion injury like ARDS
late: chronic rejection = chronic bronchiolitis obliterans
Merkel cell carcinoma
rare cutaneous malignancy that often arises in elderly males and in those with a history of immunosuppression
LOCALLY AGGRESSUCE
RISK OF METS
Tx: WLE 1-2 margin with SLNB
Radiate postop if 1+ cm
No chemotherapy
dx of merkels cell carcinoma
Bx (IHC)
[negative]: cytokeratin 20 [negative] and TTF-1 (lung), S100 (melanoma)
[positive]: CK and LMW CK markers with paranuclear dot like pattern
workup of merkels cell
must r/o regional mets before LN resection
living donor risk index favorable factors?
younger than 40, death due to trauma, cold ischemic time less than 8 hours, local organ procurement, and a whole ***non-DCD organ
warm ischemia time
cessation of arterial inflow to the kidney to the time of perfusion with preservation solution.
The length of warm ischemia time is particularly important in determining postoperative organ function.
cold ischemia time
initiation of cold perfusion to the time of reestablishment of arterial inflow in the transplanted kidney
how to assess donor kidney function PRECISELY?
Isotropic methods, such as a MAG-3 or DTPA renal scans.
measure the glomerular filtration rate (GFR).
azathioprine
MOA:
adverse: dose related bone marrow suppression (reduce dose, or stop), HEPATOtoxicity, pancreatitis, neoplasia, anemia, pulmonary fibrosis
transplant renal artery stenosis
<5% cases
75% of all post transplant vascular complication
usually within first 6 mos (can occur whenever tho)
dx: duplex, peak systolic > 200 cm/sec = dx
»» MRA or CTA
tx: perc transluminal angioplasty +/- stent
muromonab-CD3
antiCD3 murine mab
binds CD3 associated with T cell receptor, leading to initial activation and cytokine release followed by blockage
basiliximab
anti-CD25 chimeric mab
bind IL-2R CD25 on activated T cells preventing IL2 mediated activation
alemtuzumab
anti CD 52 humanized mab
binds to CD52 expressed on most T/B … depletes
belatacept
CTLA-4 Ig homolob
binds CD80/CD86 and prevents costim through CD28
testing hepatic arterial flow
if celiac is stenosed, then need to test the SMA-GDA-proper flow before you take the GDA
panel reactive antibody
detects preformed RECIPIENT Abs via panel of HLA typing cells
(mix donor lymphocytes with recipient serum just like crossmatch)
if high PRA, CI to TXP (increased risk of hyperacute rejection)
minimal acceptable WBC # in immunosuppression
3K
MC complication kidney txp
urine leak
MC presentation of a external ureteral compression after txp
lymphocele in 3 weeks…. decreased UOP with fluid collection
tx: perc drainage vs peritoneal window
pathology of ATN
hydrophobic changes … dilation and loss of tubules
postop diuresis mediators
urea and glucose
lab abnormality of acute venous thrombosis after kidney txp
new proteinuria
how much life is gained from a kidney txp
15 years
5 yr kidney graft survival
70% ; 65% cad, 74% living
HCV in retransplanted liver
you’ll reinfect itH
HBV with treatment in retransplanted
reinfection decrease by 20%
pretreatment txp with hepatocellular carcinoma
usually get neoadjuvant chemo with tumor ablation or TACE
macrosteatosis
in donor liver… is risk factor for primary nonfunction
MC complication liver txp
bile leak
Mc cause postop abscess after liver txp
hepatic artery thrombosis
cholangitis pathology
PMN around portal triad (NOT A MIXED INFILTRATE OR WHATEVER)
liver acute rejection pathology
T cell mediated to blood vessels (HLA Ag in kidney)
portal triad lymphocytosis, endothelitis (MIXED INFILTRATE), bile duct injry
in 1-2 mos
liver chronic rejection pathology
- disappearing bile ducts (Ab and cellular attack)
- gradually bile duct obstruction with increase in AlkPhos
- portal fibrosis
retransplantation rate liver
20%
5 yr survival rate LIVER
70%
how long to regerate liver
6-8 wks
indication for heart txp
<1 yr survival
pulmonary HTN after heart txp
early mortality
tx with inhaled NO (ECMO if severe)
acute heart rejection pathology
perivascular lymphocytic infiltrate with varying grades of myocyte inflammation and necrosis
exclusion criteria for lung donor
aspiration
mod-large contusion
purulent sputum
infiltrate
PO2 < 350 on 100% FiO2 and PEEP 5